CYP2B6 Antibody

說明書

中文名稱：

CYP2B6兔多克隆抗體
貨號：

CSB-PA001956
規(guī)格：

￥1090
圖片：
Western Blot analysis of HT29 cells using CYP2B6 Polyclonal Antibody
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情

產(chǎn)品詳情

Uniprot No.：

P20813
基因名：

CYP2B6
別名：

1,4 cineole 2 exo monooxygenase antibody; 11B1 antibody; CP2B6_HUMAN antibody; CPB 6 antibody; CPB6 antibody; CYP 2B6 antibody; CYP IIB6 antibody; CYP2B antibody; CYP2B6 antibody; CYP2B7 antibody; CYP2B7P antibody; CYPIIB6 antibody; Cytochrome P450 2B6 antibody; Cytochrome P450 family 2 subfamily B antibody; Cytochrome P450 family 2 subfamily B polypeptide 6 antibody; Cytochrome P450 IIB1 antibody; Cytochrome P450 phenobarbital inducible antibody; Cytochrome P450 subfamily IIB (phenobarbital inducible) antibody; Cytochrome P450 subfamily IIB (phenobarbital inducible) polypeptide 6 antibody; Cytochrome P450 subfamily IIB polypeptide 6 antibody; EFVM antibody; IIB1 antibody; P450 antibody; P450 IIB1 antibody; P450IIB1 antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Synthesized peptide derived from the Internal region of Human CYP2B6.
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
產(chǎn)品提供形式：

Liquid
應用范圍：

WB, IHC, IF, ELISA

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:2000
IHC	1:100-1:300
IF	1:200-1:1000
ELISA	1:5000

Protocols：

Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
ELISA Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

功能：

A cytochrome P450 monooxygenase involved in the metabolism of endocannabinoids and steroids. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the epoxidation of double bonds of arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling. Hydroxylates steroid hormones, including testosterone at C-16 and estrogens at C-2. Plays a role in the oxidative metabolism of xenobiotics, including plant lipids and drugs. Acts as a 1,4-cineole 2-exo-monooxygenase.; Allele 2B6*9: Has low affinity for anandamide and can only produce 11,12 EpETrE-EAs.
基因功能參考文獻：
1. Case Reports: CYP2B6-deficient alleles may be responsible for an increased conversion of ifosfamide into neurotoxic metabolites, leading to encephalopathy. PMID: 29319893
2. The concentration-time curve (AUC(0(R)96)), maximum plasma concentration (Cmax), and terminal half-life (t1/2) values of Bupropion in CYP2B6*1/*4 were lower than those of CYP2B6*1/*1. The hydroxybupropion (HBUP) Cmax values in CYP2B6*4/*6 and CYP2B6*1/*4 increased by 1.12-fold and 1.97-fold, whereas the HBUP Cmax value in CYP2B6*1/*6 decreased to a value 1.64-fold lower than that in CYP2B6*1/*1 PMID: 29637923
3. CYP2B6-efavirenz analog complex provides a useful platform to investigate computationally as well as biophysically the effect of genetic polymorphisms on binding of the widely studied efavirenz. PMID: 29596329
4. results indicate that the amino acid substitutions in the CYP2B6 variants suppressed the metabolic activation of CPS. CYP2B6 variants have altered capacity to bioactivate CPF and may affect individual susceptibility of CPF PMID: 29463407
5. The findings of this study indicate that CYP2B6 contribute to the metabolism of MDMA to MDA in humans PMID: 28117133
6. The first data of several CYP2B6 polymorphisms in Roma population. PMID: 29095103
7. With consensus recommendations on downregulation, CYP2C induction, and CYP2B6 positive control. PMID: 28646080
8. Genotyping of CYP2B6 may therefore be of value when assessing dose requirements in methadone maintenance treatment. PMID: 28723731
9. Genomic variation in CYP2B6 may explain, at least in part, severity of Neonatal Abstinence Syndrome PMID: 28320034
10. CYP2B6 haplotype predicts efavirenz plasma concentration in black South African HIV-1-Infected children. PMID: 28816644
11. This is the first study that investigated the impact of the 516 G>T polymorphism of the CYP2B6 gene among HIV-positive individuals from southern Brazil. Its clinical significance indicates the need for prospective studies in this population. PMID: 28492729
12. G(516)T CYP2B6 polymorphisms was associated with Bronchopulmonary Dysplasia susceptibility in Preterm Neonates. PMID: 28081574
13. The deficient CYP2B6 516 T allele is associated with higher efavirenz plasma drug levels and more frequent central nervous system-related symptoms. PMID: 28145050
14. Males with the CYP2B6 *6/*6 genotype may be less susceptible to the development of anti-tuberculosis drug-induced hepatotoxicity. PMID: 28389387
15. CYP2B6 interindividual variability was not significantly associated with genetic variation in CYP2B6, nor was it associated with differences in gender or ethnicity, suggesting that factors other than these are largely responsible for the wide range of variability in CYP2B6 expression and activity observed among a large group of individuals/samples. PMID: 26608082
16. Established the regression models for CYP3A4 and CYP2B6 inductions in human hepatocytes using azole compounds. PMID: 27208383
17. Phe206 plays a crucial role in determining the specificity of CYP2B6. PMID: 27538916
18. Homozygous carriers of CYP2B6*6 allele may be at increased risk for EFV-induced QT interval prolongation via inhibition of hERG. PMID: 27333947
19. Genetic variations in CYP2B6 affect induction of Bupropion hydroxylation by sodium ferulate. PMID: 23840296
20. CYP2B6 SNPs are associated with methadone fatalities. contributes to a poor metabolizer phenotype for methadone in these fatal cases PMID: 28184434
21. CYP2B6 rs2279343 may predict event-free survival in rhabdomyosarcoma PMID: 27388155
22. It has been established that cytochrome P4502B6 (CYP2B6) is the major isoform catalyzing both ketamine N-demethylation and ketamine metabolism overall in vitro at therapeutic concentrations and clinically. PMID: 27763887
23. polymorphism c.516G>T in the CYP2B6 gene and BMI affect the metabolism rate of propofol and may play an important role in the optimisation of propofol anaesthesia PMID: 27826892
24. his cross-sectional, pharmacogenetic candidate, gene pilot study recruited 75 patients having minor elective outpatient surgeries. EP was measured with the Clinician Administered Dissociative State Scale. Genetic association of CYP2B6*6 and GRIN2B (rs1019385 and rs1806191) single-nucleotide polymorphisms and ketamine-induced EP occurrence and severity were tested using logistic and linear regression. PMID: 28252572
25. Data suggest that A785G CYP2B6 gene polymorphisms and specific CYP2B6 haplotypes may be a risk factor for the pathogenesis of AML, especially secondary AML as well as for the induction of AML chromosomal aberrations. PMID: 27865701
26. Results show that CYP2B6 slow metabolizer genotypes were significantly associated with efavirenz induced central nervous system symptoms. PMID: 27509478
27. The possible influence of CYP2B6 c.516G>T genetic variant on propofol dose. PMID: 26141406
28. Around 450 and 250 mg daily doses might meet EFV dosing needs of HIV-TB infected Ugandans in general and CYP2B6*6/*6 genotypes, respectively. PMID: 27045425
29. CYP2B6 polymorphisms were associated with lower and higher plasma concentrations in pregnant and postpartum women. PMID: 27195527
30. Analysis of gene-gene interactions with CYP2B6 was particularly useful to reinforce the role of MRP4 and to reveal unknown associations, such as that of DRD3. PMID: 27665700
31. POR rs2868177 and CYP2B6*6 variants contribute to the interindividual variability in human CYP2B6 activity, which may affect the disposition and interaction of other CYP2B6 substrate drugs PMID: 27439448
32. CYP2B6*6 and *9 variant alleles had a significant decreasing effect on sertraline metabolism in major depression patients. PMID: 26830411
33. Combined 3D-QSAR and docking procedures yielded precise information about the common and distinct interactions of inhibitors and the enzyme active sites of CYP2B6. PMID: 26648056
34. the cytochrome P450 oxidoreductase g.6593A>G polymorphism significantly influences CYP2B6 activity PMID: 26580670
35. Observation in Chinese patients with systemic lupus erythematosus indicated that the combination genetic marker of CYP2C19*2 and CYP2B6 -750 T > C genotypes was associated with 4-OH-CPA plasma concentration, short term efficacy and adverse reactions of cyclophosphamide. PMID: 26456622
36. Data suggest that primary cytochrome P450 in liver microsomes catalyzing 9-hydroxylation of (-)-cis- and (-)-trans-rose oxide is CYP2B6 (and CYP2C19 to some extent); rose oxide is aroma compound from essential oils and is used in food and perfume. PMID: 26126958
37. CYP2B6 516G>T SNP is prevalent in Aregntinian population. PMID: 26681005
38. Both Cyp2b6 CT/TT genotype of rs8192719 (c.1294 + 3C > T) and AG genotype of rs2279343 (c.785A > G) prolonged survival (p < 0.05). PMID: 26602960
39. Data suggest peripheral ligand-binding pocket and active site are located on opposite sides of the I-helix in CYP2B6; similar results were obtained for CYP2B4. PMID: 26982502
40. Report shift in substrate specificity with sequence element swaps between CYP2B6 and CYP2B11. PMID: 27015760
41. gene expression experiment revealed that CYP2B6, SPON1, and GSG1L can be activated concomitantly through a constitutive androstane receptor (CAR) activation pathway PMID: 27010727
42. POR besides CYP2B6 can influence cyclophosphamide metabolism PMID: 26544874
43. The CYP2B6*6 allele is associated with decrease plasma clearance and may be associated with a higher incidence of ketamine adverse effects. PMID: 25702819
44. Average efavirenz concentrations of patients carrying ACTG (1.78 mug/mL), ACCT (7.50 mug/mL), and ATTG (1.92 mug/mL) haplotypes were markedly higher than those of patients carrying the CCTG haplotype. PMID: 26107645
45. CYP2B6 Gene Polymorphism is not associated with Acute Myeloid Leukemia. PMID: 26107207
46. The results provide evidence that the 516 TT homozygous genotype in the CYP2B6 gene presents a significant protective effect on the development of liver toxicity caused by anti-tuberculosis drugs. PMID: 25271170
47. Studied the extent to which CYP2B6 and NAT2 polymorphisms were associated increased efavirenz concentrations in black and Hispanic patients enrolled from sub-Saharan Africa and South America. PMID: 25722197
48. An increase in minor allele frequencies for CYP2B6 (and CYP2D6)was found in Roma population samples. PMID: 25933954
49. significantly reduce the success of autologous HCT for lymphoma patients with the CYP2B6*5 variant. PMID: 25677220
50. Functional importance of a peripheral pocket in mammalian cytochrome P450 2B enzymes. PMID: 26319176
顯示更多

收起更多
亞細胞定位：

Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein.
蛋白家族：

Cytochrome P450 family
組織特異性：

Expressed in liver, lung and heart right ventricle.
數(shù)據(jù)庫鏈接：

HGNC: 2615

OMIM: 123930

KEGG: hsa:1555

STRING: 9606.ENSP00000324648

UniGene: Hs.1360

Most popular with customers

YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human
VDAC1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human, Mouse, Rat
VCP Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, IP

Species Reactivity: Human, Rat